Massachusetts Medicaid and GLP-1 coverage

Here is the regulation's own paragraph. Under "Limitations on Coverage of Drugs," in its Drug Exclusions subsection, paragraph (7) of 130 CMR 406.413(B) reads: "Obesity and Overweight Management. The MassHealth agency does not pay for any drug used for the treatment of obesity or overweight." The next subsection keeps the door open for children: the limitations and exclusions "do not apply to medically necessary drug therapy for MassHealth Standard and CommonHealth enrollees younger than 21 years old." The page footers carry transmittal PHM-65 and the date 07/03/26.

Massachusetts Executive Office of Health and Human Services, MassHealth Pharmacy Manual, 130 CMR 406.000 (Pharmacy Services), transmittal PHM-65, effective July 2026 · source

The transmittal letter, dated July 2026 and signed by the MassHealth Chief Pharmacy Officer, says what the amendment does in one sentence: "The amendments also end coverage of drugs prescribed solely for the treatment of obesity or overweight, except for children covered by the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) program." And when: "These amendments are effective July 3, 2026."

MassHealth, Transmittal Letter PHM-65 (Revised Program Regulations, 130 CMR 406.000), effective July 2026 · source

The announcement came four months ahead, in Pharmacy Facts number 271, dated March 12, 2026: "MassHealth will no longer cover drugs used for the treatment of obesity or overweight. Effective July 3, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members, when used for weight loss." Table 1 names benzphetamine, diethylpropion, Saxenda, Xenical, phendimetrazine, Lomaira and Adipex-P, Wegovy and Zepbound. It also explains what happened to approvals already in hand: prior authorizations for these agents "submitted before February 17, 2026, will be end-dated for July 2, 2026, regardless of indication and will need to be resubmitted," and that the GLP-1 drugs stay covered past that date for members with approved authorizations for other accepted uses, listing cardiovascular risk reduction, liver disease and sleep apnea.

MassHealth, Pharmacy Facts, Number 271 (Corrected), effective March 2026 · source

Pharmacy Facts number 276, dated May 13, 2026, settles who it applies to. After restating the July 3 date it says: "This applies to all members, whether enrolled in Fee for Service (FFS); managed care organizations (MCOs); Program of All-inclusive Care for the Elderly (PACE); accountable care partnership plans (ACPP); primary care accountable care organizations (PCACOs); and Primary Care Clinician (PCC), Senior Care Options (SCO), or One Care plans." The same issue reshuffles the remaining uses: from July 3, 2026 "Wegovy® (semaglutide) will be the sole preferred drug for ALL other medically accepted indications," and "Zepbound® (tirzepatide) will no longer be a preferred drug."

MassHealth, Pharmacy Facts, Number 276 (Corrected), effective May 2026 · source

The August list reflects it. The MassHealth Drug List published August 10, 2026 carries Wegovy as "PA; PD; See Table 72" and Zepbound as "PA; See Table 72," under a class the list calls "Miscellaneous GIP/GLP-1 and GLP-1 Receptor Agonists." The criteria in that table require, for cardiovascular risk reduction, a body mass index of 27 or more dated within the prior 90 days plus established cardiovascular disease, and for sleep apnea a body mass index of 30 or more and an apnea-hypopnea index of at least 15 events per hour, with a quantity limit of four pens per 28 days. Saxenda returns zero matches across the list and there is no anti-obesity class; the list's introduction says drugs excluded under 130 CMR 406.413(B) "are not available to MassHealth adult members. Prescribers may request PA for such drugs for members under 21 years old." The list's own change summary for July 2026 records the former anti-obesity table being removed.

MassHealth, MassHealth Drug List (published August 10, 2026), effective August 2026 · source

The history, from the state's own newsletter of November 19, 2024: "MassHealth began covering anti-obesity medications in January 2024." That same issue announced that "Effective January 1, 2025, Wegovy® (semaglutide) and Saxenda® (liraglutide) will be non-covered agents" for weight loss, with Zepbound the preferred GLP-1 for that use at the time. So the coverage that ended in July 2026 had already narrowed once, eighteen months earlier.

MassHealth, Pharmacy Facts, Number 235, effective November 2024 · source

The fair hearing rules publish two windows. They say the Board of Hearings must receive a request "60 days after an applicant or member receives written notice from the MassHealth agency of the intended action," and "it will be presumed that the notice was received on the fifth day after mailing." For a managed care plan's decision the window is "120 days after the member's receipt of the managed care contractor's final internal appeal decision," and the right to that hearing exists "provided the member has exhausted all remedies available through the managed care contractor's internal appeals process." To keep a drug you already receive while the hearing is pending, the request has to reach the Board "within ten days of the mailing of the notice of the appealable action." This edition of the rules carries Eligibility Letter 241, revised December 23, 2022.

Massachusetts Executive Office of Health and Human Services, 130 CMR 610.000 (MassHealth Fair Hearing Rules), §§610.015, 610.032 and 610.036, effective December 2022 · source